Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
| ▸ | FASN | P49327 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348309 | 0.90 | KDM5C (0.45) | L3MBTL1ACKR3FASNNPC1POLB | |
| SCHEMBL348308 | 0.89 | ACKR3 (0.44) | L3MBTL1ACKR3FASNNPC1POLB | |
| SCHEMBL13458595 | 0.88 | L3MBTL1 (0.42) | L3MBTL1ACKR3FASNNPC1POLB | |
| SCHEMBL347706 | 0.88 | ACKR3 (0.43) | L3MBTL1ACKR3FASNNPC1POLB | |
| SCHEMBL347273 | 0.85 | ALDH1A1 (0.43) | L3MBTL1ACKR3FASNNPC1POLB | |
| SCHEMBL347099 | 0.79 | PRKAA2 (0.44) | L3MBTL1ACKR3EPHX2 | |
| SCHEMBL347188 | 0.79 | ALDH1A1 (0.44) | L3MBTL1ACKR3FASNNPC1POLB | |
| SCHEMBL347189 | 0.79 | ALDH1A1 (0.46) | L3MBTL1ACKR3NPC1POLBRAB9A | |
| SCHEMBL348551 | 0.78 | L3MBTL1 (0.41) | L3MBTL1FASNNPC1POLBRAB9A | |
| SCHEMBL346910 | 0.77 | ALDH1A1 (0.41) | L3MBTL1ACKR3NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | L3MBTL1 3842/4885ACKR3 1675/4885FASN 1591/4885 |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | PEPD, PREP, ACE | L3MBTL1 3990/4885ACKR3 1327/4885FASN 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.